FDA Clearance Tracker · K223515
MamaLift Plus
Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Apr 22, 2024
Substantially Equivalent
Time to decision
517 days
Received Nov 22, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K223515
- Device name
- MamaLift Plus
- Applicant
- Curio Digital Therapeutics, Inc.
- Applicant location
- Princeton, NJ
- Received
- Nov 22, 2022
- Decided
- Apr 22, 2024
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 882.5801
- Specialty
- Neurology & Neurosurgery
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code SAP. The earliest in FDA's data is K231209, decided Mar 30, 2024.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K223515
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Curio Digital Therapeutics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.